Gilmore Neil O'Neill - Jun 5, 2023 Form 4 Insider Report for Editas Medicine, Inc. (EDIT)

Role
CEO, Director
Signature
/s/ Gilmore O'Neill
Stock symbol
EDIT
Transactions as of
Jun 5, 2023
Transactions value $
-$61,638
Form type
4
Date filed
6/7/2023, 04:30 PM
Previous filing
Mar 6, 2023
Next filing
Jun 26, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % Price $ Shares After Date Ownership Footnotes
transaction EDIT Common Stock Sale -$61.6 K -6.49 K -4.75% $9.50 130 K Jun 5, 2023 Direct F1, F2

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on April 13, 2022, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on June 2, 2023. The sale does not represent a discretionary trade by the Reporting Person.
F2 This transaction was executed in multiple trades at prices ranging from $9.4600 to $9.5034. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.